Biovest announces interim blinded data of fast-tracked pivotal Phase 3 clinical trial of BiovaxID
Worcester, Mass. June 28, 2007 -- Biovest International, Inc. (OTCBB: BVTI), a majority owned subsidiary of Accentia Biopharmaceuticals, Inc. (NASDAQ:ABPI), announced on June 27, 2007 blinded interim data from the start of its fast-tracked pivotal Phase 3 clinical trial of BiovaxID for Non-Hodgkins lymphoma (NHL) from September 2000 through June 2006. This interim blinded data is the most rece...